Janer given nod as Fischer CTO

Mar 10, 2003

Mammography vendor Fischer Imaging has hired Roman Janer as its chief technology officer director. Janer served as vice president of technology for Hologic from May 2000 until his move to Fischer, and has held key positions at companies such as Trex Medical as well as Picker International where he was head of worldwide x-ray research and development for 16 years, according to Denver-based Fischer.

By AuntMinnie.com staff writers
March 11, 2003

Related Reading

Fischer taps Broda, January 20, 2003

Fischer expands board of directors, January 15, 2003

Fischer sales fall, firm dips into red, November 14, 2002

Fischer gets extension to delisting stay, October 24, 2002

Cardle joins Fischer Imaging, October 21, 2002

Copyright © 2003 AuntMinnie.com

Latest in Womens Imaging
Mri Breast 400
NME breast lesions have high malignancy rate on MRI-guided biopsy
August 10, 2026
Breast Cancer 400
Many women interested in AI-based risk assessment for breast cancer
August 10, 2026
(A) Free-response receiver operating characteristic (FROC) curve for DBT-DINO and DINOv2 (Meta AI) on the detection task. DINOv2 achieved higher sensitivity than DBT-DINO across most false-positive thresholds. (B) Detection rates of DBT-DINO and DINOv2 for lesions that were ultimately found to be benign (n = 70) and lesions that were found to be cancerous (n = 66). Error bars represent 95% CIs estimated via patient-level bootstrapping with 1000 repetitions. Both models showed similar detection rates for cancerous lesions, whereas DINOv2 detected more benign lesions than DBT-DINO. (C) Example bounding box predictions for DBT-DINO and DINOv2 on the detection test set. Each image is a single two-dimensional section from a three-dimensional digital breast tomosynthesis volume; the first column shows a mediolateral oblique view, and the second and third columns show craniocaudal views. Both models struggled to detect very small lesions, such as the 3-mm-diameter lesion shown in the first column. FP = false positive.
DBT-based foundational model classifies breast density
August 4, 2026
Research Money 400
Medara nets $400,000 NCI grant for AI breast cancer risk platform
August 4, 2026
Related Stories
187x200 Am Logo
Companies
AuntMinnie.com
Hologic Logo
Brachytherapy Seeds & Systems
Hologic EU
2003 01 27 15 24 03 706
RSNA
Breast abscess in lactating women resolved with ultrasound-based detection, treatment
2003 01 13 15 29 39 706
Breast
Start-up firm Photonify sees promise in optical imaging
More in Womens Imaging
NME breast lesions have high malignancy rate on MRI-guided biopsy
By Amerigo Allegretto
Biopsies from women with a known ipsilateral malignancy have a higher frequency of breast cancer.
August 10, 2026
Mri Breast 400
Many women interested in AI-based risk assessment for breast cancer
By Amerigo Allegretto
Survey findings also show that most women at higher risk are interested in additional screening tests.
August 10, 2026
Breast Cancer 400
DBT-based foundational model classifies breast density
By Amerigo Allegretto
DBT-DINO showed strong performance in classifying breast density from DBT images.
August 4, 2026
(A) Free-response receiver operating characteristic (FROC) curve for DBT-DINO and DINOv2 (Meta AI) on the detection task. DINOv2 achieved higher sensitivity than DBT-DINO across most false-positive thresholds. (B) Detection rates of DBT-DINO and DINOv2 for lesions that were ultimately found to be benign (n = 70) and lesions that were found to be cancerous (n = 66). Error bars represent 95% CIs estimated via patient-level bootstrapping with 1000 repetitions. Both models showed similar detection rates for cancerous lesions, whereas DINOv2 detected more benign lesions than DBT-DINO. (C) Example bounding box predictions for DBT-DINO and DINOv2 on the detection test set. Each image is a single two-dimensional section from a three-dimensional digital breast tomosynthesis volume; the first column shows a mediolateral oblique view, and the second and third columns show craniocaudal views. Both models struggled to detect very small lesions, such as the 3-mm-diameter lesion shown in the first column. FP = false positive.
Medara nets $400,000 NCI grant for AI breast cancer risk platform
By AuntMinnie.com staff writers
The platform combines longitudinal mammographic imaging with clinical risk factors to predict short-term breast cancer risk.
August 4, 2026
Research Money 400
Women's Imaging MinnieCast, Episode 14: GLP-1s and breast cancer risk
By Amerigo Allegretto
Elizabeth McDonald, MD, shares results from her team's study on how GLP-1s may have beneficial effects on breast cancer risk.
July 31, 2026
Minnie Cast Thumbnail (17)
RadSite publishes clinical coverage guideline for breast CBCT imaging
By AuntMinnie.com staff writers
The guide outlines how breast CBCT should be used when conventional imaging approaches are inconclusive or inaccessible.
July 30, 2026
Rad Site
CEM finds breast cancer at baseline, incidence screening
By Amerigo Allegretto
Incidence screening with CEM maintains high performance and may offer more benefits over baseline CEM screening.
July 28, 2026
Images in a 70-year-old asymptomatic woman with a prior excisional biopsy in the left breast yielding lobular carcinoma in situ 3 years earlier. Screening contrast-enhanced mammography (CEM) was performed, which was considered a prevalence screen as the woman had no prior breast MRI in the past 3 years and no prior CEM. (A) Low-energy (26–30 kVp) mediolateral oblique (MLO) and (B) craniocaudal (CC) views show surgical clips but no abnormality. (C) Recombined MLO and (D) CC images show an enhancing mass in the medial left breast (arrows). Biopsy revealed invasive lobular carcinoma. Size was 0.2 cm; tumor grade II/III; negative lymph nodes; and estrogen receptor–positive, progesterone receptor–positive, and human epidermal growth factor receptor 2–negative.
QT Imaging nets Israeli registration for Breast Acoustic CT scanner
By AuntMinnie.com staff writers
The registration authorizes commercialization of the company's Breast Acoustic CT Scanner in Israel through early 2028.
July 28, 2026
Breast Self Exam2 400
Uterine fibroid assessment differs by imaging technique
By Amerigo Allegretto
MRI and ultrasound differ in mapping uterine fibroids in women undergoing laparoscopic-assisted robotic myomectomy.
July 27, 2026
Uterus Pelvic 400 (1)
Women's Imaging MinnieCast, Episode 13: Partial breast irradiation in the spotlight
By Amerigo Allegretto
Two committee members for ASTRO's PBI guidelines share insights about this breast cancer treatment option.
July 17, 2026
Minnie Cast Thumbnail (15)
Incorrect AI suggestions influence reader performance on mammography
By Amerigo Allegretto
The biggest impact on reader performance stemmed from false-negative AI suggestions.
July 14, 2026
A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.
Breast cancer screening higher among civically engaged women
By Amerigo Allegretto
Women who voted, attended a public meeting, or volunteered are more likely to get their breast cancer screening.
July 14, 2026
Mammogram Calendar 400
Page 1 of 710
Next Page